You just read:

Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)

News provided by

Amgen

Feb 15, 2016, 04:00 ET